NCT00442923 (MARC) is a Phase 2 clinical trial of Coreg in Anxiety, sponsored by Aaron J. Janowsky.

Who is sponsoring NCT00442923?

NCT00442923 is sponsored by Aaron J. Janowsky.

What drugs are being tested in NCT00442923?

Interventions in NCT00442923: Coreg.

What condition does NCT00442923 study?

NCT00442923 studies Anxiety, Relapse, Substance Addiction.

Is NCT00442923 still recruiting?

NCT00442923 is currently withdrawn. Last updated 31 January 2019.

Last reviewed 2019-01-31 · How we verify

NCT00442923: MARC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"The Evaluation of Stimulant Withdrawal"

Withdrawn Phase 2 Last updated 31 January 2019

What this trial tests

Phase 2 trial testing Coreg in Anxiety. Withdrawn.

Timeline

1 July 2007

Primary endpoint
30 June 2010

30 June 2011

Quick facts

Lead sponsor	Aaron J. Janowsky
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Start date	1 July 2007
Primary completion	30 June 2010
Estimated completion	30 June 2011
Sites	1 location across United States

Drugs / interventions tested

Coreg — full drug profile →

Conditions studied

Anxiety — all drugs for Anxiety →
Relapse — all drugs for Relapse →
Substance Addiction — all drugs for Substance Addiction →

Sponsor

Aaron J. Janowsky — full company profile →

Who can join

Adults 18 to 65, any sex, with Anxiety or Relapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to determine whether Carvedilol, an FDA approved beta blocker, when administered for an 8-week period to veterans currently undergoing treatment for methamphetamine dependence (1) improves their ability to stay in treatment longer, (2)eases the aversive symptoms that accompany stimulant withdrawal, and (3) increases the time they remain abstinent from methamphetamine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00442923 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aaron J. Janowsky
Last refreshed: 31 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00442923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing